Literature DB >> 6466536

Second look laparotomy in the management of epithelial cell carcinoma of the ovary.

G M Mead, C J Williams, F R MacBeth, I E Boyd, J M Whitehouse.   

Abstract

Case histories from 20 patients undergoing postchemotherapy "second look" laparotomy for metastatic epithelial cell carcinoma of the ovary were reviewed in an attempt to evaluate the usefulness of this procedure and its likely impact on patient survival. The patient population comprised 18 patients treated with a combination of cisplatin, adriamycin and cyclophosphamide (PACe) and 2 patients treated with chlorambucil. The findings at second look were often predictable, and related to the adequacy of initial surgery. Complete tumour regression identified a group of patients with a relatively good prognosis. However in most patients residual tumour was found which rarely proved resectable. Second line chemotherapy was poorly tolerated, and appeared to have little impact on the disease particularly after combination chemotherapy had been used initially. There was little evidence that second look surgery itself positively contributed to survival. This procedure and its timing should be regarded as experimental and a suitable subject for randomised clinical trials.

Entities:  

Mesh:

Year:  1984        PMID: 6466536      PMCID: PMC1976862          DOI: 10.1038/bjc.1984.161

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).

Authors:  J Carmo-Pereira; F O Costa; E Henriques; J A Ricardo
Journal:  Cancer       Date:  1981-11-01       Impact factor: 6.860

2.  Acute leukemia after alkylating-agent therapy of ovarian cancer.

Authors:  R R Reimer; R Hoover; J F Fraumeni; R C Young
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

3.  Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.

Authors:  C T Griffiths
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

4.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

Authors:  R C Young; B A Chabner; S P Hubbard; R I Fisher; R A Bender; T Anderson; R M Simon; G P Canellos; V T DeVita
Journal:  N Engl J Med       Date:  1978-12-07       Impact factor: 91.245

5.  Second-look operation in ovarian carcinoma: postchemotherapy.

Authors:  J P Smith; G Delgado; F Rutledge
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

6.  Second-look operations in the planned management of advanced ovarian carcinoma.

Authors:  K S Raju; J A McKinna; G H Barker; E Wiltshaw; J M Jones
Journal:  Am J Obstet Gynecol       Date:  1982-11-15       Impact factor: 8.661

7.  Role of cytoreductive surgical treatment in the management of advanced ovarian cancer.

Authors:  C T Griffiths; L M Parker; A F Fuller
Journal:  Cancer Treat Rep       Date:  1979-02

8.  Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination.

Authors:  C J Williams; B Mead; A Arnold; J Green; R Buchanan; M Whitehouse
Journal:  Cancer       Date:  1982-05-01       Impact factor: 6.860

9.  A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.

Authors:  G A Omura; C P Morrow; J A Blessing; A Miller; H J Buchsbaum; H D Homesley; L Leone
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

10.  Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.

Authors:  M H Greene; J D Boice; B E Greer; J A Blessing; A J Dembo
Journal:  N Engl J Med       Date:  1982-12-02       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.